News

This Emergency Use Listing (EUL) of this single-shot vaccine opens up the door to much of the developing world to gain access to it.

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.

Strong immunologic responses to vaccination for SARS-CoV-2 in COVID-19 survivors suggest that first of 2-dose vaccination could suffice.

According to one new study, proton-pump inhibitors (PPI) exposure demonstrated a moderate increase in the risk of community-acquired C diff infection.

Macrolide-resistant strains of Streptococcus pneumoniae account for almost 40% of infections overall, a new study found.

The analysis highlights the importance of high-frequency testing as a complement to social distancing, vaccination, and other mitigation strategies.

Managing mental health in adults living with HIV is paramount during the COVID-19 pandemic.

Series completion rates were different among patient groups, the study authors observed.

While at the earliest stages of potential development, long-acting/extended release (LA/ER) formulations for treatment and prevention of TB could be something to be studied in the future.

Index testing declined in countries including Malawi, Lesotho and Zimbabwe.

Deep learning models identified the largest differences in resting state network topology occurred.

Plasma proteome confirmed the association between cellular and humoral SARS-CoV-2 immunity.

The prognostic proteins identified can serve as the basis of future pathway and network analyses.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

Johns Hopkins data suggest men are being hospitalized more frequently with infection, and are facing more severe outcomes.

MN titers showed a striking increase after just 1 dose in experienced subjects.

COVID-19 has further highlighted the need for innovative models that minimize face-to-face contact in HCV treatment.

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

Convalescent plasma treatment was found not to improve survival or disease course in the patient group.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

Gut microbiome is known to release enzymes that degrade plasma glycans which regulate inflammation.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

14 weeks of oral alendronate taken prior to ART had a sustained impact on prevention of bone loss at the hip.

Increased hospitalization risk was driven mainly by the high burden of comorbidities in both groups.

Change was associated with risk factors that have not been reported like chronic lung disease.